Estimated Glucose Disposal Rate (eGDR), a validated tool to estimate insulin sensitivity (IS) in T1DM [eGDR = 21.158 - (0.09 x WC, cm) - (3.47 x hypertension, yes = 1) - (0.551 x HbA1c, %)], has been associated to all-cause death. The relationship between eGDR and major vascular (CV) events was evaluated in 736 T1DM enrolled in an observational, single-centre study over a 10-year follow-up. Incidence of CV and coronary events were obtained by interrogating hospital discharge registers. Mean eGDR was 7.51±2.26 (M±SD) mg/kg/min (median 8.26; IQR 5.53-9.29). According to the “Swedish National Diabetes Register,” eGDR was stratified in: C1: ≥8.0 (N. 399, 54.2%, ref); C2: 6.0-7.99 (N. 121, 16.4%); C3: 4.0-5.99 (N. 144, 19.6%) and C4: <4.0 mg/kg/min (N. 72, 9.8%). Compared to C1, C2-4 showed a worse risk profile. A total of 49 CV events (defined as first of MI, stroke, coronary, carotid or peripheral revascularization) occurred over a follow-up of 10.38±2.88 years (6.7%, 6.42 x1000 PYs). By Kaplan-Meier, incidence increased across eGDR categories: C1, 2.3%; C2, 4.1% (HR [95% CI] 1.79 [0.60-5.35]); C3, 11.8% (5.68 [2.53-12.75]); C4, 25.0% (12.76 [5.73-28.43], p<0.0001). After adjustment for multiple confounders, risk of CV events was significantly increased in C4 (5.18 [2.11-12.72], p<0.0001). Further adjustment for variables strictly related to IS (HDL, triglycerides, ACR) did not exclude C4 eGDR as an independent covariate. Over a follow-up of 10.47±2.74 years, 35 coronary events (first of MI or coronary revascularization) occurred (4.8%; 4.54 x 1000 PYs). Incidence increased across eGDR categories: C1, 2.3%; C2, 0.8% (0.35 [0.04-2.76]); C3, 7.6% (3.65 [1.51-8.81]); C4, 19.4% (9.64 [4.17-22.30], p<0.0001). After adjustment for multiple confounders, risk of coronary events was significantly increased in C4 (4.78 [1.90-12.04], p=0.001). Even so after further adjustment for variables strictly related to IS. Thus, in our T1DM, eGDR was a long-term independent predictor of vascular events.

Disclosure

M. Garofolo: None. E. Gualdani: None. R. Giannarelli: None. M. Aragona: None. F. Campi: None. D. Lucchesi: None. G. Daniele: None. R. Miccoli: None. P. Francesconi: None. S. Del Prato: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi, Servier, Takeda Pharmaceutical Company Limited. Board Member; Self; AstraZeneca. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited. G. Penno: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.